"The U.S. Food and Drug Administration today cleared a new screening test that predicts a patient's risk of future coronary heart disease (CHD) events, such as heart attacks.
FDA cleared the test for use in all adults with no history of hear"...
Do not administer DEFINITY® to patients with known or suspected:
- Right-to-left, bi-directional, or transient right-to-left cardiac shunts,
- Hypersensitivity to perflutren [see WARNINGS AND PRECAUTIONS].
Do not administer DEFINITY® by intra-arterial injection.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 8/31/2015
Additional Definity Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.